‘Global Plasma Fractionation Market Set To Grow To $40bn By 2023’ says newly published Visiongain research

30 July 2018
Pharma

Visiongain’ has launched a new pharma report Global Plasma Fractionation 2018-2028: Immunoglobulins, Albumins, Clotting Factors, Hyperimmune Globulins, Alpha 1 Antitrypsin Inhibitors (A1PI), C1 Esterase Inhibitors, Primary Immune Deficiency (PID), Secondary Immune Deficiency (SID), Idiopathic Thrombocytopenic Purpura (ITP), Cardiac & Surgery, Emergency Medicine, Haemophilia

In this report, we examined the global plasma fractionation market including the major submarkets by product, application, region and national market. The industry consists of a small number of high-capacity commercial fractionators with extensive multinational operations, and a large number of medium to small fractionators, which have lower outputs and exist primarily to serve national markets.

The lead analyst of the report commented “Aside from the growth in the scale of the industry, there has been an increasing sophistication in the processes that ensure the safety and quality of products; a greater use of chromatography in fractionation technologies; a concentration of the industry into fewer hands; and shifts in the patterns of clinical usage for the various plasma-fractionated products. The key drivers of demand for fractionation services have also changed over time as new plasma products have become commercially available and new indications for the use of plasma products have been identified and adopted.”

Leading companies featured in the report include

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 208 781 6953

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cancer Diagnostics Market Report 2021-2031

Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.

19 April 2021

Read

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever